Myeloid Leukemia News and Research

RSS
Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.
Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS

Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS

8 Jun 2011
Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

7 Jun 2011
FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

FDA lifts BioSante's GVAX Prostate Cancer Vaccine clinical hold

7 Jun 2011
Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

Ridaforolimus Phase III SUCCEED clinical trial on metastatic sarcoma meets primary endpoint

7 Jun 2011
Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

7 Jun 2011
Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

Interim results from CTI, Chroma Therapeutics' tosedostat phase II trial on AML presented at ASCO

6 Jun 2011
Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer

Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer

4 Jun 2011
Key findings from Phase I clinical trial of CPI-613 in AML to be presented at ASCO 2011

Key findings from Phase I clinical trial of CPI-613 in AML to be presented at ASCO 2011

4 Jun 2011
ARIAD's ponatinib initial Phase 1 study data on acute myeloid leukemia to be presented at ASCO 2011

ARIAD's ponatinib initial Phase 1 study data on acute myeloid leukemia to be presented at ASCO 2011

3 Jun 2011
EpiCept completes $10.6 million 11.5% senior secured term loan facility with MidCap Financial

EpiCept completes $10.6 million 11.5% senior secured term loan facility with MidCap Financial

31 May 2011
Leukemia protein plays a role in Alzheimer's disease

Leukemia protein plays a role in Alzheimer's disease

25 May 2011
Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

21 May 2011
New study sheds light on origins of myeloid leukemia

New study sheds light on origins of myeloid leukemia

13 May 2011
Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

Trillium raises $1 million to advance TTI-1612 into clinical trials for interstitial cystitis treatment

12 May 2011
Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

12 May 2011
Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio first quarter total revenue increases to $3.1 million for 2011

11 May 2011
EpiCept first quarter net loss decreases to $2.5 million

EpiCept first quarter net loss decreases to $2.5 million

10 May 2011
CytRx reports $6.3 million net loss for first quarter 2011

CytRx reports $6.3 million net loss for first quarter 2011

5 May 2011
ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

20 Apr 2011
Clontech releases iDimerize inducible dimerization systems

Clontech releases iDimerize inducible dimerization systems

20 Apr 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback